First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

•A consensus on the use of ICIs in lung cancer patients with PS 2 is lacking.•An International Expert Panel Meeting was held in 2021 to review and discuss available evidence on this topic.•Overall, agreement was reached on the safety of ICI monotherapy in PS 2 patients, with concerns for chemo–ICI combinations.•Common considerations were reached on the priorities for clinical research to investigate PS 2 lung cancer population.